E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Extremely low gestational age neonates (ELGANs), i.e. those who are born at <28 weeks gestation and who uniformly suffer from intermittent hypoxemic episodes. |
|
E.1.1.1 | Medical condition in easily understood language |
Very premature infants who uniformly suffer from episodes with insufficient oxygen concentrations in their blood (and consecutively insufficient oxygen delivery to their organs). |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10006475 |
E.1.2 | Term | Bronchopulmonary dysplasia |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10038933 |
E.1.2 | Term | Retinopathy of prematurity |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10055667 |
E.1.2 | Term | Necrotising enterocolitis neonatal |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10011912 |
E.1.2 | Term | Death neonatal |
E.1.2 | System Organ Class | 10018065 - General disorders and administration site conditions |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10071101 |
E.1.2 | Term | Primary apnoea of premature newborns |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the effect of efficacy of closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C) provided in standard infant ventilators in addition to manual adjustments of the inspired oxygen fraction (FiO2) during mechanical ventilation, continous positive airway pressure (CPAP) or any other positive pressure respiratory support compared to manual adjustments of the FiO2 only on the primary endpoints. |
|
E.2.2 | Secondary objectives of the trial |
To assess the safety of FiO2-C. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Gestational Age at birth 23+0/7 to 27+6/7 weeks |
|
E.4 | Principal exclusion criteria |
• Decision not to provide full life support / decision for palliative care only before study entry • Severe congenital abnormalities (particularly those affecting respiratory, cardiovascular, or gastrointestinal function or long-term neuro-cognitive development, whereas a patent ductus arteriosus or a PFO/ASDII is not considered a congenital anomaly in preterm infants) • Postnatal age >48h • Missing parental consent • Lack of device enabling closed-loop automatic control of FiO2 before randomization
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint: Composite outcome of death, severe retinopathy of prematurity, chronic lung disease or necrotizing enterocolitis until 36 weeks PMA or (for ROP) until full vascularization of the retina.
Subordinate co-primary endpoint: Composite outcome of death, language/ cognitive delay, motor impairment, severe visual impairment or hearing impairment at 24 months corrected age.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Primary endpoint: at a postmenstrual age of 36 weeks for (for the components death, BPD, NEC) and when full retinal vascularisation is reached for ROP
Subordinate co-primary endpoint: the age of 24 months corrected for prematurity |
|
E.5.2 | Secondary end point(s) |
Individual components of the primary outcome variables and developmental scores of the Bayley Scales of Infant Development (3rd edition). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
at a postmenstrual age of 36 weeks at the time when full vascularisation of the retina is reached at the age of 24 months corrected for prematurity |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
partially observer-blinded |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
The comparator will be routine manual adjustments of FiO2 by bedside nurse and medical staff |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 50 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 100 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
12 months after LVLS Jusitification for delayed "end of study date": our experience in multinational, multicenter trials with limited public funding is, that database entries of follow-up visits are delayed because of incomplete/missing data e.g., due to delegated follow-up examination to external sites (to meet needs of the families involved) etc.. Consequently, database and site closure as well as end of study may be delayed. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 6 |